A CMOS-Based Multiomics Detection Platform for Simultaneous Quantification of Proteolytically Active Prostate-Specific Antigen and Glutamate in Urine

By combining information such as genomics, proteomics, and metabolomics data, multiomics methodologies have the potential to reveal the otherwise invisible processes of carcinogenesis. Using these data, a new-generation point-of-care (POC) device may support patient care through rapid diagnosis involving accurate and simultaneous multiomics measurements. In this work, we present a proof-of-concept portable system capable of measuring a metabolite (glutamate) and a protein [proteolytically active prostate-specific antigen (aPSA)] simultaneously on a single device in a 2-min interval using on-chip optical methods. The device has the potential to improve the current diagnostic pathways of prostate cancer (PCa) by reducing the high false-positive rate with the widely used total prostate-specific antigen (tPSA) test. We demonstrate a simultaneous assay of glutamate and aPSA in buffer and synthetic urine. For the glutamate assay, the limit of detection (LOD) and resolution were found to be 0.9 and
$2.7 {\boldsymbol {\mu }}\text{M}$
, respectively. The LOD and resolution for aPSA were 0.5 and 2.0 ng
$/$
ml, respectively. The LOD and resolution achieved using this device are, therefore, in line with human physiological ranges. The platform is suitable for accommodating two independent optical assays, and, therefore, chemistry can be modified to measure different analytes regardless of their nature. This technological breakthrough has the potential to deliver an accurate multiomics portable device for PCa and may be extended to other diseases.